An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
biote Corp. (Nasdaq: BTMD) will release its Q2 2022 financial results on August 9, 2022, after market close. A conference call is scheduled for 8:30 a.m. ET on August 10, 2022, where CEO Terry Weber will discuss these results and provide a business update. Biote, a leader in hormone optimization, went public on May 27, 2022. The company offers a range of support to certified practitioners, enhancing hormone therapy through education and software solutions.
Positive
Biote went public on May 27, 2022, presenting growth opportunities.
Focus on hormone optimization may cater to growing demand in healthcare.
Negative
Risks related to the COVID-19 pandemic impacting market conditions.
Regulatory scrutiny in the pharmacy compounding industry poses challenges.
IRVING, Texas--(BUSINESS WIRE)--
biote Corp. (“Biote” or the “Company”) (Nasdaq: BTMD), a high growth, medical practice-building business within the hormone optimization space, will report its financial results for the second quarter ended June 30, 2022, after market close on Tuesday, August 9, 2022. Terry Weber, Chief Executive Officer, and the Company’s management will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET on Wednesday, August 10, 2022.
The link will also be posted in the Investor Relations section of the Biote website, found here. A replay of the webcast will be available shortly after the event concludes.
About Biote
Biote is a woman-led company that provides third-party certified practitioners with a suite of services to create, develop, and implement a personalized program designed to optimize patient hormone levels. The company provides certified practitioners with education, training & certification, practice & inventory management software, and marketing support, as well as a database of related clinical research and prior patient information. Biote went public on Nasdaq on May 27, 2022. To learn more about Biote, please visit www.biote.com.
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the federal U.S. securities laws with respect our expectations regarding future growth, performance, business prospects and opportunities, future plans and intentions or other future events. These forward-looking statements generally are identified by words such as “anticipate”, “believe”, “expect”, “may”, “could”, “will”, “potential”, “intend”, “estimate”, “should”, “plan”, “predict”, or the negative or other variations of such statements, reflect our management’s current beliefs and assumptions and are based on the information currently available to our management. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements, including but not limited to: the ability to implement business plans, forecasts and other expectations, and identify and realize additional opportunities; the risk of downturns in the market and Biote’s industry including, but not limited to, as a result of the COVID-19 pandemic; risks and uncertainties related to Biote’s business, including, but not limited to, those related to regulation, its supply chain, its executive influence, its limited operating history, highly competitive markets and competition, data privacy and cybersecurity, its ability to grow, its financial condition and potential dilution, its forecasts, expansion, intellectual property, current or future litigation, capital requirements and the need for additional capital, physician training, relationships with physicians, its key employees and qualified personnel, third-party manufacturers, regulatory scrutiny of the pharmacy compounding industry, health care fraud and abuse, HIPAA, and its dietary supplement business. The foregoing list of factors is not exclusive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the proxy statement and other documents filed by Biote from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and Biote does not assume any obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Biote does not give any assurance that it will achieve its expectations.
